LT3734B - Use of bambuterol for the manufacture of a pharmaceutical preparation with lipid lowering effect - Google Patents
Use of bambuterol for the manufacture of a pharmaceutical preparation with lipid lowering effect Download PDFInfo
- Publication number
- LT3734B LT3734B LTIP1735A LTIP1735A LT3734B LT 3734 B LT3734 B LT 3734B LT IP1735 A LTIP1735 A LT IP1735A LT IP1735 A LTIP1735 A LT IP1735A LT 3734 B LT3734 B LT 3734B
- Authority
- LT
- Lithuania
- Prior art keywords
- bambuterin
- manufacture
- cholesterol
- bambuterol
- lowering effect
- Prior art date
Links
- 230000000694 effects Effects 0.000 title claims abstract description 12
- 150000002632 lipids Chemical class 0.000 title claims abstract description 7
- 238000004519 manufacturing process Methods 0.000 title claims abstract 3
- ANZXOIAKUNOVQU-UHFFFAOYSA-N bambuterol Chemical compound CN(C)C(=O)OC1=CC(OC(=O)N(C)C)=CC(C(O)CNC(C)(C)C)=C1 ANZXOIAKUNOVQU-UHFFFAOYSA-N 0.000 title abstract 2
- 229960003060 bambuterol Drugs 0.000 title abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 125000006318 tert-butyl amino group Chemical group [H]N(*)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- DWLVWMUCHSLGSU-UHFFFAOYSA-M n,n-dimethylcarbamate Chemical compound CN(C)C([O-])=O DWLVWMUCHSLGSU-UHFFFAOYSA-M 0.000 claims 1
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 8
- 229960000195 terbutaline Drugs 0.000 description 8
- 102000004895 Lipoproteins Human genes 0.000 description 7
- 108090001030 Lipoproteins Proteins 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 108010007622 LDL Lipoproteins Proteins 0.000 description 5
- 102000007330 LDL Lipoproteins Human genes 0.000 description 5
- 230000008604 lipoprotein metabolism Effects 0.000 description 5
- 238000008214 LDL Cholesterol Methods 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 208000031225 myocardial ischemia Diseases 0.000 description 4
- 102000003914 Cholinesterases Human genes 0.000 description 3
- 108090000322 Cholinesterases Proteins 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 108010028554 LDL Cholesterol Proteins 0.000 description 3
- 239000000048 adrenergic agonist Substances 0.000 description 3
- 229940048961 cholinesterase Drugs 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 206010048650 Cholinesterase inhibition Diseases 0.000 description 2
- 101100379247 Salmo trutta apoa1 gene Proteins 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 102100033639 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102100022119 Lipoprotein lipase Human genes 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- IEJIGPNLZYLLBP-UHFFFAOYSA-N dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000012740 non-selective inhibitor Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9000948A SE9000948D0 (sv) | 1990-03-16 | 1990-03-16 | New use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LTIP1735A LTIP1735A (en) | 1995-07-25 |
| LT3734B true LT3734B (en) | 1996-02-26 |
Family
ID=20378886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTIP1735A LT3734B (en) | 1990-03-16 | 1993-12-30 | Use of bambuterol for the manufacture of a pharmaceutical preparation with lipid lowering effect |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US5837727A (cs) |
| EP (1) | EP0521967B1 (cs) |
| JP (1) | JP3081640B2 (cs) |
| KR (1) | KR100194995B1 (cs) |
| AT (1) | ATE138570T1 (cs) |
| AU (1) | AU653149B2 (cs) |
| CA (1) | CA2077762C (cs) |
| CZ (1) | CZ279308B6 (cs) |
| DE (1) | DE69119896T2 (cs) |
| DK (1) | DK0521967T3 (cs) |
| EG (1) | EG19645A (cs) |
| ES (1) | ES2087291T3 (cs) |
| GR (1) | GR3020700T3 (cs) |
| HK (1) | HK52197A (cs) |
| HU (1) | HU211998B (cs) |
| IE (1) | IE80668B1 (cs) |
| IL (1) | IL97509A (cs) |
| LT (1) | LT3734B (cs) |
| LV (1) | LV10917B (cs) |
| MY (1) | MY114218A (cs) |
| NZ (1) | NZ237279A (cs) |
| PT (1) | PT97052B (cs) |
| RU (1) | RU2093153C1 (cs) |
| SE (1) | SE9000948D0 (cs) |
| SG (1) | SG64895A1 (cs) |
| SK (1) | SK278815B6 (cs) |
| WO (1) | WO1991013615A1 (cs) |
| ZA (1) | ZA911452B (cs) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9000948D0 (sv) * | 1990-03-16 | 1990-03-16 | Draco Ab | New use |
| US6459316B1 (en) * | 2000-12-08 | 2002-10-01 | Intel Corporation | Flip flop circuit |
| KR20040068240A (ko) * | 2001-12-14 | 2004-07-30 | 노보 노르디스크 에이/에스 | 호르몬 민감성 리파아제의 활성을 감소시키기 위한 화합물및 그들의 사용 |
| US7495028B2 (en) | 2002-08-08 | 2009-02-24 | Wen Tan | R-bambuterol, its preparation and therapeutic uses |
| AU2002332488A1 (en) * | 2002-08-08 | 2004-02-25 | J. L. Cheng | R-bambuterol, its preparation and therapeutic uses |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0043807A2 (en) | 1980-07-09 | 1982-01-13 | Aktiebolaget Draco | 1-(Dihydroxyphenyl)-2-amino-ethanol derivatives; preparation, compositions and intermediates |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4472436A (en) * | 1982-12-06 | 1984-09-18 | Neo-Bionics, Inc. | Increasing HDL-cholesterol levels with phenylethylamine derivatives |
| EP0244062A3 (en) * | 1986-03-03 | 1990-06-20 | Beecham Group Plc | Use of aryl ethanol amine derivatives in the treatment of atherosclerosis |
| SE9000948D0 (sv) * | 1990-03-16 | 1990-03-16 | Draco Ab | New use |
-
1990
- 1990-03-16 SE SE9000948A patent/SE9000948D0/xx unknown
-
1991
- 1991-02-27 ZA ZA911452A patent/ZA911452B/xx unknown
- 1991-03-01 NZ NZ237279A patent/NZ237279A/en unknown
- 1991-03-11 IL IL9750991A patent/IL97509A/en not_active IP Right Cessation
- 1991-03-13 EG EG14791A patent/EG19645A/xx active
- 1991-03-13 MY MYPI91000414A patent/MY114218A/en unknown
- 1991-03-14 EP EP91906760A patent/EP0521967B1/en not_active Expired - Lifetime
- 1991-03-14 ES ES91906760T patent/ES2087291T3/es not_active Expired - Lifetime
- 1991-03-14 RU SU915053006A patent/RU2093153C1/ru active
- 1991-03-14 CA CA002077762A patent/CA2077762C/en not_active Expired - Lifetime
- 1991-03-14 WO PCT/SE1991/000195 patent/WO1991013615A1/en not_active Ceased
- 1991-03-14 JP JP03507053A patent/JP3081640B2/ja not_active Expired - Lifetime
- 1991-03-14 AT AT91906760T patent/ATE138570T1/de not_active IP Right Cessation
- 1991-03-14 HU HU9202958A patent/HU211998B/hu unknown
- 1991-03-14 DK DK91906760.3T patent/DK0521967T3/da active
- 1991-03-14 AU AU75691/91A patent/AU653149B2/en not_active Expired
- 1991-03-14 DE DE69119896T patent/DE69119896T2/de not_active Expired - Lifetime
- 1991-03-14 SG SG1996005904A patent/SG64895A1/en unknown
- 1991-03-15 IE IE86291A patent/IE80668B1/en not_active IP Right Cessation
- 1991-03-15 US US07/670,053 patent/US5837727A/en not_active Expired - Lifetime
- 1991-03-15 SK SK681-91A patent/SK278815B6/sk unknown
- 1991-03-15 PT PT97052A patent/PT97052B/pt not_active IP Right Cessation
- 1991-03-15 CZ CS91681A patent/CZ279308B6/cs not_active IP Right Cessation
-
1992
- 1992-09-15 KR KR1019920702222A patent/KR100194995B1/ko not_active Expired - Lifetime
-
1993
- 1993-06-30 LV LVP-93-816A patent/LV10917B/lv unknown
- 1993-12-30 LT LTIP1735A patent/LT3734B/lt not_active IP Right Cessation
-
1996
- 1996-07-31 GR GR960402068T patent/GR3020700T3/el unknown
-
1997
- 1997-04-24 HK HK52197A patent/HK52197A/en not_active IP Right Cessation
-
1998
- 1998-11-17 US US09/193,940 patent/US6034123A/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0043807A2 (en) | 1980-07-09 | 1982-01-13 | Aktiebolaget Draco | 1-(Dihydroxyphenyl)-2-amino-ethanol derivatives; preparation, compositions and intermediates |
Non-Patent Citations (2)
| Title |
|---|
| T. GORDON, V.P. KASTELLI, IR KT: "Aukšto tankio lipoproteinai, kaip apsauginis faktorius prieš išeminę širdies ligą, farmacinis tyrmas", AM . J. MED 62, 1977, pages 707 - 714 |
| V.P. KASTELLI, J.T. DOIL IR KT: "ATL-cholesterinas ir kiti lipidai sergant išemine širdies liga", THE COOPERATIVE LIPOPROTEIN PHENOTYPING STUDY, 1997, pages 767 - 772 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU686706B2 (en) | Inhibition of smooth muscle migration and proliferation with hydroxy carbazole compounds | |
| US20040242634A1 (en) | Methods for treating prion diseases | |
| JPH1067663A (ja) | ミルタザピンと１種以上の選択的セロトニン再取り込み阻害剤とを含む医薬組成物 | |
| US4929605A (en) | Pharmaceutical composition for piperidinoalkanol derivatives | |
| JP2004196821A (ja) | ベータ−２−気管支拡張薬の改善使用 | |
| SA93140384B1 (ar) | كربامات الفينيل | |
| US20020132855A1 (en) | Use of acetaminophen to prevent and treat arteriosclerosis | |
| Abe et al. | Agents for the treatment of glycosphingolipid storage disorders | |
| IL323233A (en) | A combination containing a monoamine antidepressant and a short-term psychedelic | |
| LT3734B (en) | Use of bambuterol for the manufacture of a pharmaceutical preparation with lipid lowering effect | |
| US20080255079A1 (en) | Therapeutic Use of Nefopam and Analogues Thereof | |
| US20020055533A1 (en) | Pharmaceutical composition | |
| US6194460B1 (en) | Composition for treating cough induced by angiotensin converting enzyme inhibitors | |
| CA1209047A (en) | Therapeutic composition containing piracetam analog | |
| GB2189703A (en) | Vinpocetine | |
| SK18072002A3 (sk) | Farmaceutické prípravky obsahujúce betablokátor a ich použitie | |
| EP1314423A1 (en) | Medicinal compositions | |
| KR20010013685A (ko) | 케탄제린 및 ｌ-카르니틴 또는 알카노일 ｌ-카르니틴을함유하는 ｃｒｐｓ 치료용 조성물 | |
| JP2003501385A (ja) | Ｈｍｇ−ｃｏａレダクターゼ阻害剤とカルニチン類を含む抗高脂血症性組合せ | |
| US4073940A (en) | Method for treating cardiac arhythmia by administration of basic aryloxyacetamide | |
| CA1280695C (en) | Nalbuphine-local anesthetic analgesic composition and method of producing analgesia | |
| US5843938A (en) | Treatment of atherosclerosis | |
| WO1996036337A1 (en) | New use | |
| Breivik et al. | Relief of postoperative pain with zomepirac, paracetamol with codeine, or placebo | |
| EP1656933A1 (en) | A medicinal composition comprising L-alanine for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis and use therof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM9A | Lapsed patents |
Effective date: 19971230 |